塔爾蘇斯製藥公司（納斯達克股票代碼：TARS）報告每股虧損$(0.60)，優於分析師預期的每股虧損$(0.75)，超出預期20%。與去年同期每股虧損$(1.31)相比，提高了54.2%。公司報告的季度銷售額爲$66.41百萬，超出了分析師預期的$58.33百萬，增長了13.85%。與去年同期銷售額爲$13.08百萬相比，增長了407.86%。

以上內容來自Benzinga Earnings專欄，原文如下：

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.75) by 20 percent. This is a 54.2 percent increase over losses of $(1.31) per share from the same period last year. The company reported quarterly sales of $66.41 million which beat the analyst consensus estimate of $58.33 million by 13.85 percent. This is a 407.86 percent increase over sales of $13.08 million the same period last year.